Drug Profile
BAY 1193397
Alternative Names: BAY-1193397Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer
- Class Cardiovascular therapies; Vascular disorder therapies
- Mechanism of Action Alpha 2c adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peripheral arterial disorders
Most Recent Events
- 23 Feb 2022 No development reported - Phase-II for Peripheral arterial disorders in United Kingdom (PO)
- 28 Oct 2019 Bayer completes a phase II trial in Peripheral arterial disorders in United Kingdom (PO) (NCT03128320) (EudraCT2015-003799-63)
- 25 May 2017 Phase-II clinical trials in Peripheral arterial disorders in United Kingdom (PO) (NCT03128320)